NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment)...
Preventing Antimicrobial Resistance Together Antimicrobial resistance (AMR) describes the situation when microorganisms (bacteria, fungi, parasites and viruses) no longer respond to the drugs (antimicrobials) that are used to treat infections. As a consequence,...
Agreement will initially cover the UK and France with potential to expand to other European countries and worldwide NEWCASTLE UPON TYNE, UK, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care molecular...
The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation...
Diagnosing, treating and managing respiratory infections NEWCASTLE UPON TYNE, UK, 5 July 2022. QuantuMDx Group Limited (“QuantuMDx”) will be offering insights and advice on tackling respiratory infections in the wake of the pandemic during a webinar later this month....